Search company, investor...

Predict your next investment

Venture Capital
emeraldmanagers.com

See what CB Insights has to offer

Investments

21

About Emerald Development Managers

Emerald Development Managers is an early stage/growth equity investor. The firm has a distinct and highly-disciplined, long-term investment strategy to drive the creation of valuable companies by providing investment capital, guidance, and hands-on experience in the development, ownership and operation of early stage companies and projects. To facilitate this drive to value, the firm seeks to partner with highly-motivated and creative management teams to bring their concepts to life.

Headquarters Location

909 3rd Ave Floor 15

New York, New York, 10022,

United States

212-317-2250

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Emerald Development Managers News

Torigen Pharmaceuticals Announces Completion of $13 Million Capital Raise

Nov 17, 2022

Venture Capital News | Private Equity News venture capital directory | private equity directory Venture Capital Firms List / Venture Capital & Private Equity Firms and Sources Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory 2022 Newly Updated Edition Now Available! (Updated JULY 2022) VCPro Database 2022 25th Edition — a downloadable and searchable venture capital database with 6,800+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. Torigen Pharmaceuticals Announces Completion of $13 Million Capital Raise FARMINGTON, Conn., November 16, 2022-- Torigen Pharmaceuticals, Inc, a commercial-stage animal health biologics company, today announced it has closed its $13 million Series A1 round led by Werth Family Investment Associates, LLC and Connecticut Innovations, Inc., bringing the total raised by the company to $18 million. Existing investors Emerald Development Managers, Gaingels, Kema Fund, University of Notre Dame, SoGal Ventures, and UCONN Innovation Fund, LLC participated in the round. New investors in this round also included Ironwood Capital and Advantage Capital. “Our goal is to create the industry’s first oncology toolbox for veterinarians,” said Ashley Kalinauskas, CEO and co-founder of Torigen Pharmaceuticals. “This round of funding will allow us to continue to develop new products and leverage our pipeline. We are excited to work with all our investors as we expand our platform and continue to help the millions of pets diagnosed with cancer and other immune-mediated diseases each year.” “Our investment in Torigen is grounded in the same values and principles that guide us at Werth Ventures,” said Musan Duric, Investment Portfolio Manager, Werth Ventures. “As a family office, we focus on growing the good in business and life, supporting women entrepreneurs, and championing change within the animal health market. Torigen’s lead product, VetiVax, is a prime example of the company’s ability to deliver innovative products and access the veterinary market. We’re committed to seeing Torigen succeed and look forward to accompanying the entire team on its journey.” “Torigen is a transformative animal health tech company that creates personalized cancer immunotherapies, making effective cancer treatment more accessible and affordable for pet owners,” said Neil Cohen, Chairman, Emerald Development Managers. “The work Torigen has done to date is exceptional. The team has developed a deep understanding of animal oncology, allowing them to develop new treatments to cover additional animal health conditions. We look forward to supporting Torigen’s growth and to collaborating with Connecticut Innovations, Werth, and all those invested in the company’s success.” To meet the market’s strong demand, Torigen is now recruiting a skilled salesforce. Postings for open roles can be found at http://www.torigen.com. About Torigen Pharmaceuticals Inc: Torigen is transforming pet cancer treatment by harnessing the pet's immune system to create personalized cancer immunotherapies, making pet cancer treatment more accessible and more affordable. Torigen recognizes the instrumental role pets play in our families and is determined to extend the lives of companion animals despite a cancer diagnosis. With over 50% of all dogs over the age of 10 dying from cancer, Torigen is dedicated to providing affordable and effective cancer care solutions for all companion animals. Torigen is a spin-out from the University of Notre Dame and backed by Werth Family Investment Associates, Connecticut Innovations, Emerald Development Managers, Ironwood Capital, Advantage Capital, The University of Connecticut, The University of Notre Dame, SoGal Ventures, Gaingels, and other prominent investors. For more information visit http://www.torigen.com.

Emerald Development Managers Investments

21 Investments

Emerald Development Managers has made 21 investments. Their latest investment was in Torigen Pharmaceuticals as part of their Series A - II on November 11, 2022.

CBI Logo

Emerald Development Managers Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/17/2022

Series A - II

Torigen Pharmaceuticals

$13M

Yes

3

6/30/2022

Series C

Evolved by Nature

$120M

Yes

5

6/6/2022

Series B

CybSafe

$28M

Yes

7

6/3/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

12/28/2021

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/17/2022

6/30/2022

6/6/2022

6/3/2022

12/28/2021

Round

Series A - II

Series C

Series B

Series C

Private Equity

Company

Torigen Pharmaceuticals

Evolved by Nature

CybSafe

Subscribe to see more

Subscribe to see more

Amount

$13M

$120M

$28M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

3

5

7

10

10

Emerald Development Managers Team

3 Team Members

Emerald Development Managers has 3 team members, including , .

Name

Work History

Title

Status

Neil Cohen

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Neil Cohen

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.